Stratagene settles litigation, strengthens patent portfolio

By Lisa Kerner

Erie, Pa., May 16 - Stratagene Corp. said it and Takara Bio Inc. agreed to resolve the companies' patent disputes in the field of enzyme blends that are widely used in polymerase chain reaction (PCR) technology used to amplify small amounts of DNA and detect diseases such as cancer, heart disease, AIDS and viral hepatitis.

The agreement settles all pending patent litigation in the U.S. District Court for the District of Maryland and resolves all actual and potential patent interference proceedings in the U.S. Patent & Trademark Office.

Cross-licenses of the companies' respective patent rights relating to enzyme blends will avoid potential future disputes, according to a company news release.

"We are very pleased with the outcome of our settlement agreement with Takara Bio Inc. as it significantly strengthens our patent position in PCR technology," Stratagene president and chief executive officer Joseph A. Sorge stated in the release.

"We believe that there are a number of competitors selling products that are covered under our patent portfolio. It is our intention to make limited licenses available and recognize resulting licensing revenue."

Located in La Jolla, Calif., Stratagene develops and markets specialized life science research and diagnostic products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.